DRW Securities’s Cyclerion Therapeutics CYCN Stock Holding History

DRW Securities’s Portfolio CYCN Stock Details CYCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-43,617	Closed	-$100K	–	1328
2025 Q3	$100K	Buy	+43,617	New	+$118K	﹤0.01%	1184

Other funds holding CYCN

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

DRW Securities's CYCN Position: Q4 2025 in Review

DRW Securities sold out of Cyclerion Therapeutics (CYCN) in Q4 2025, closing a stake of 43,617 shares — an estimated $100K sold.

DRW Securities first reported a position in CYCN in Q3 2025 and held it in 1 quarter. The position peaked at $100K in Q3 2025. 19 funds tracked by Wall St. Rank hold CYCN as of Q4 2025.

DRW Securities reported no remaining Cyclerion Therapeutics position as of Q4 2025 after selling out during the quarter.
DRW Securities sold 43,617 Cyclerion Therapeutics shares in Q4 2025, an estimated $100K.
DRW Securities first reported a position in Cyclerion Therapeutics in Q3 2025 and held it in 1 quarter.
DRW Securities's Cyclerion Therapeutics position peaked at $100K in Q3 2025.
19 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2025.

Based on DRW Securities's 13F filing for Q4 2025, filed 12 Feb 2026.